Gilead Announces Phase 2 Study Results for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma at ASH

Gilead Sciences

today announced results of a Phase 2 study (Study 101-09) evaluating idelalisib, an investigational oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin's lymphoma (iNHL) that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. In this study, single-agent treatment with idelalisib achieved an overall response rate of 57 percent with a median duration of response of 12.5 months. The data were presented today during an oral session at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans (Abstract #85). “It has been more than ten years since a treatment with a novel mechanism of action has been approved for indolent NHL, underscoring